文 献104 1）Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-731. 2）Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J 2022; 60: 2102311. 3）Rhee SJ, Shin SH, Oh J, Jung YH, Choi CW, Kim HS, et al. Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension. Sci Rep 2022; 12: 7393. 4）Miyakawa S, Odagiri K, Inui N, Hakamata A, Goto T, Tanaka S, et al. Short-term drug-drug interaction between sildenafil and bosentan under long-term use in patients with pulmonary arterial hypertension. Pharmacology & Pharmacy 2013; 4: 542-8. 5）Hakamata A, Odagiri K, Miyakawa S, Irisawa H, Takeuchi K, Inui N, et al. Pharmacokinetic and pharmacodynamic comparison of sildenafil-bosentan and sildenafil-ambrisentan combination therapies for pulmonary hypertension. Clin Transl Sci 2016; 9: 29-35. 6）Tanaka S, Uchida S, Hakamata A, Miyakawa S, Odagiri K, Inui N, et al. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension, Pharmazie 2020; 75: 236-9. 7）Pharmaceuticals and Medical Devices Agency, Japan. Revatio Tablets package insert (in Japanese).[https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/671450_2190028F1021_4_07 (accessed 2025-10-4)] 8）Pharmaceuticals and Medical Devices Agency, Japan. Adcirca Tablets package insert (in Japanese).[https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/530263_2190030F1029_2_08 (accessed 2025-10-4)] 9）Pharmaceuticals and Medical Devices Agency, Japan. Tracleer 62.5mg film-coated tablets package insert (in Japanese).[https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/800155_2190026F1022_2_03 (accessed 2025-10-4)]10）Pharmaceuticals and Medical Devices Agency, Japan. Volibris Tablets package insert (in Japanese).[https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340278_2190031F1023_1_12 (accessed 2025–10–4)]11）Takatsuki S, Ikehara S, Nakayama T, Matsuura H , S a j i T . A d v a n c e d t h e r a p i e s f o r t h e pharmacological treatment of pediatric pulmonary arterial hypertension (in Japanese). Pediatric Cardiology and Cardiac Surgery 2017; 33: 297-311.12）Pharmaceuticals and Medical Devices Agency, Japan. Tracleer 32mg dispersible tablets for pediatric package insert (in Japanese).[https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/800155_2190026X1028_2_04 (accessed 2025-10-4)]13）Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013; 48: 27-34.14）Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452-8.15）Pharmaceuticals and Medical Devices Agency, Japan. Revatio Tablets Common Technical Document (in Japanese)[https://www.pmda.go.jp/drugs/2017/P20170920002/671450000_22000AMX00022_K100_1.pdf (accessed 2025-10-4)]16）Pharmaceuticals and Medical Devices Agency, Japan. Adcirca Tablets Review Report (in Japanese)[https://www.pmda.go.jp/drugs/2009/P200900050/530471000_22100AMX02266000_A100_2.pdf (accessed 2025-10-4)]
元のページ ../index.html#120